TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
    • Career
  • News & Media
    • Press Releases
    • Media Coverage
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Request Pathway Quote
    • FAQ
  • INVESTOR RELATIONS
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Stock Information
    • Investor Resources
      • FAQ
      • Contact Us
    • Corporate Governance
      • Management Team
      • Medical Advisory Board
      • Scientific Advisory Board
      • Board of Directors
  • Contact

Financial Information

Theralink   →  Financial Information

Financial Information

FINANCIAL INFORMATION

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
DATE From DESCRIPTION DOCS XBRL
02/12/21 D Notice of Exempt Offering of Securities
10/28/20 8-K Current report
10/06/20 3 Initial statement of beneficial ownership of securities
09/29/20 8-K Current report - Item 5.02 Item 9.01
09/21/20 8-K Current report - Item 1.01
08/31/20 DEFM14C Definitive information statement relating to merger or acquisition
08/26/20 8-K Current report
08/19/20 8-K/A Current report: [Amend]
08/19/20 PREM14C Preliminary information statements relating to merger or acquisition
08/17/20 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
  • 1
  • 2
  • 3
  • ...
  • 20
  • Next >>

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Technologies Moves Closer Toward Changing the Standard of Care for All Women Newly Diagnosed with HER2+ Breast Cancer
  • Theralink® Technologies Announces Milestone Event–The Commencement of Testing on its First Patients
  • Theralink® Technologies Issues Letter to Shareholders
Copyright © 2020 Theralink. All rights reserved.
We use cookies to improve your experience on our site. If you continue the use of this site then you accept our terms of use and privacy policy.Terms & Privacy